All In Biotech

Free tool

FAERS Monitor: Urocit-K

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019071 or its brand name (Urocit-K, Potassium Citrate). Reports on generic versions are filed under their own applications.

Reports

5,569

Serious

3,307

59% of reports

Hospitalization

1,734

Death reported

320

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective462
  • fatigue378
  • nausea340
  • diarrhoea339
  • pain309
  • nephrolithiasis279
  • off label use271
  • dizziness248
  • dyspnoea229
  • headache217
  • fall207
  • vomiting186
  • asthenia164
  • pneumonia161
  • arthralgia156

Reports by year received

View as table
YearReports
200416
200517
200626
200734
200835
200957
201078
2011104
2012112
2013123
2014145
2015290
2016365
2017326
2018374
2019373
2020409
2021449
2022516
2023450
2024446
2025484
2026340

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,590 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
nephrolithiasisSignal27923.120.65,856
fallSignal2072.32.1162
diarrhoea3392.01.8170
pain3091.91.7135
pneumonia1611.91.666
dizziness2481.91.7103
fatigue3781.81.7148
asthenia1641.61.442
nausea3401.61.584
dyspnoea2291.51.342
vomiting1861.51.331
arthralgia1561.41.219
drug ineffective4621.31.239
headache2171.31.116
off label use2711.21.07

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.